Fatal Anaphylaxis: Mortality Rate and Risk Factors
Autor: | Turner, PJ, Jerschow, E, Umasunthar, T, Lin, R, Campbell, DE, Boyle, RJ |
---|---|
Přispěvatelé: | Medical Research Council (MRC), Imperial College Healthcare NHS Trust- BRC Funding, National Institute for Health Research |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Incidence
Drug allergy Allergens beta-Lactams Survival Analysis United States ICD International Classification of Diseases Drug Hypersensitivity Cardiovascular Diseases Risk Factors Food allergy Quality of Life Insect sting Humans Review and Feature Article Mortality Child Anaphylaxis Arthropod Venoms |
Zdroj: | The Journal of Allergy and Clinical Immunology. in Practice |
ISSN: | 2213-2201 2213-2198 |
Popis: | Up to 5% of the US population have suffered anaphylaxis. Fatal outcome is rare, such that even for people with known venom or food allergy, fatal anaphylaxis constitutes less than 1% of total mortality risk. The incidence of fatal anaphylaxis has not increased in line with hospital admissions for anaphylaxis. Fatal drug anaphylaxis may be increasing, but rates of fatal anaphylaxis to venom and food are stable. Risk factors for fatal anaphylaxis vary according to cause. For fatal drug anaphylaxis, previous cardiovascular morbidity and older age are risk factors, with beta-lactam antibiotics, general anaesthetic agents and radiocontrast injections the commonest triggers. Fatal food anaphylaxis most commonly occurs during the second and third decades. Delayed epinephrine administration is a risk factor; common triggers are nuts, seafood, and in children milk. For fatal venom anaphylaxis, risk factors include middle-age, male sex, white race, cardiovascular disease and possibly mastocytosis; insect triggers vary by region. Upright posture is a feature of fatal anaphylaxis to both food and venom. The rarity of fatal anaphylaxis, and the significant quality of life impact of allergic conditions, suggest that quality of life impairment should be a key consideration when making treatment decisions in patients at risk for anaphylaxis. |
Databáze: | OpenAIRE |
Externí odkaz: |